Pediatric and Adolescent Osteosarcoma pp 147-164

Part of the Cancer Treatment and Research book series (CTAR, volume 152) | Cite as

The Role of Radiotherapy in Oseosarcoma

  • Rudolf Schwarz
  • Oyvind Bruland
  • Anna Cassoni
  • Paula Schomberg
  • Stefan Bielack
Chapter

Abstract

A survey of the literature shows that the experience with radiotherapy (RT) in the local treatment of osteosarcoma (OS) is limited. This is due to various reasons: OS is a rare tumor and surgery is the treatment of choice with high local control rate, and uncertainty exists in regard to the efficacy and tolerance of radiotherapy. Publications on this topic were analyzed and will be reviewed. Furthermore, experience from the Cooperative Osteosarkomstudiengruppe (COSS)-Registry, including 100 patients (pts) treated using radiotherapy for OS, was analyzed.

The COSS-registry includes a total of 175 pts (5% of all pts) with histologically proven OS irradiated over the period of 1980−2007. 100 pts were eligible for analysis. The median age was 18 (3–66) years. Indication for RT was a primary tumor in 66, a local recurrence in 11, and metastases in 23 pts. 94 pts got external photontherapy; 2 pts, proton therapy; 2 pts, neutron therapy; and 2 pts, intraoperative RT. In addition, a group of 17 pts received bone-targeted radionuclide therapy by samarium-153-EDTMP-therapy alone or in combination with external RT. The median dose for external RT was 55.8 Gy (30–120). All the pts received chemotherapy in accordance with different COSS-protocols.

The median follow-up was 1.5 (0.2–23) years. Survival and local control rates at 5 years were calculated, and univariate and multivariate analyses performed. 41 pts are alive, 59 pts died. The overall survival rate after biopsy was 41% at 5 years, while the overall survival rates after RT for the whole group, for treatment of primary tumors, local recurrence, and metastases were 36%, 55%, 15%, and 0% respectively.

In 41 cases, local control was achieved, whereas local progression or local recurrence occurred in 59 cases, with a median time to local recurrence of 0.5 (0.1–4) years after RT. 15 pts were nonresponders to radiotherapy. Local control for the whole group was 30%. Local control rates for combined surgery and RT were significantly better than those for RT alone (48% vs. 22%, p=0.002). Local control for treatment of primary tumors, local recurrence, and metastases were 40%, 17%, and 0% respectively. Local control for pts given an addition of samarium-153-EDTMP was poor, though not statistically significant . A dose of over 60 Gy had no significant effect on local control. Prognostic factors for survival were indication for RT, RT plus surgery vs. RT alone and tumor location. Prognostic factors for local control were indication for RT, and RT plus surgery vs. RT alone.

For the majority of pts, surgery remains the local treatment of choice. Radiotherapy is an important option as local treatment of unresectable tumors, following intralesional resection, or as palliation of symptomatic metastases. Survival prognosis of such pts, however, is poor. Despite the fact that many of these pts will eventually die, they may benefit in terms of prolonged survival and prolonged local control. The combination of surgery, radiotherapy, and chemotherapy can be curative. The consistent use of full-dose chemotherapy is of importance for the response to radiotherapy. Prognostic factors for survival are indication for RT, RT plus surgery vs. RT alone and tumor location. Prognostic factors for local control are indication for RT, and RT plus surgery vs. RT alone.

References

  1. 1.
    Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.PubMedGoogle Scholar
  2. 2.
    Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Paediatr. 1999;211:260-270.Google Scholar
  3. 3.
    Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292-315.CrossRefPubMedGoogle Scholar
  4. 4.
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76-84.PubMedGoogle Scholar
  5. 5.
    Weis LD. The success of limb-salvage surgery in the adolescent patient with osteogenic sarcoma. Adolesc Med. 1999;10:451-458.PubMedGoogle Scholar
  6. 6.
    Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma: the University of Muenster experience. Clin Orthop. 1999;358:83-89.CrossRefPubMedGoogle Scholar
  7. 7.
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative oseosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.CrossRefPubMedGoogle Scholar
  8. 8.
    Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcomas of the extremities. Ann Oncol. 1997;8:899-903.CrossRefPubMedGoogle Scholar
  9. 9.
    Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the cooperative osteosarcoma study group. J Clin Oncol. 2003;21:334-341.CrossRefPubMedGoogle Scholar
  10. 10.
    Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the cooperative osteosarcoma study group. Cancer. 2002;94:1069-1077.CrossRefPubMedGoogle Scholar
  11. 11.
    Kassir RR, Rassekh CH, Kinsella JB, et al. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies. Laryngoscope. 1997;107:56-61.CrossRefPubMedGoogle Scholar
  12. 12.
    Jenkin RD, Allt W, Fitzpatrick PJ. Osteosarcoma: an assessment of management with particular reference to primary irradiation and selective delayed amputation. Cancer. 1972;2:393-400.CrossRefGoogle Scholar
  13. 13.
    De Moor NG. Osteosarcoma: a review of 72 cases treated by megavoltage radiation therapy, with or without surgery. S Afr J Surg. 1975;13:137-146.PubMedGoogle Scholar
  14. 14.
    Beck JC, Wara WM, Bovill EG Jr, et al. The role of radiation therapy in the treatment of osteosarcoma. Radiology. 1976;120:163-165.PubMedGoogle Scholar
  15. 15.
    Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1:79-111.PubMedGoogle Scholar
  16. 16.
    Gaitan-Yanguas M. A study of the response of osteogenic sarcoma and adjacent normal tissues to radiation. Int J Radiat Oncol Biol Phys. 1981;7:593-595.CrossRefPubMedGoogle Scholar
  17. 17.
    Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 2003;78:147-155.CrossRefPubMedGoogle Scholar
  18. 18.
    DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Rad Oncol Biol Phys. 2005;61:492-498.CrossRefGoogle Scholar
  19. 19.
    Bruland ØS, Skretting A, Solheim ØP, et al. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncologica. 1996;35:381-384.CrossRefPubMedGoogle Scholar
  20. 20.
    Bruland ØS, Skretting A, Saeter G, et al. Targeted internal radiotherapy in osteosarcoma patients using 153Sm-EDTMP. Med Ped Oncol. 1996;27:215.Google Scholar
  21. 21.
    Bruland ØS, Phil A. On the current management of osteosarcoma: a critical evaluation and proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725-1731.CrossRefPubMedGoogle Scholar
  22. 22.
    Anderson PM, Wisemann GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamnine tetramethylene phosphonate phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:189-196.CrossRefPubMedGoogle Scholar
  23. 23.
    Franzius C, Bielack S, Sciuk J, et al. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38:337-340.PubMedGoogle Scholar
  24. 24.
    Franzius C, Schuck A, Bielack SS. High-dose Samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:1953-1954.PubMedGoogle Scholar
  25. 25.
    Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma Relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol. 2005;23:559-568.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.CrossRefGoogle Scholar
  27. 27.
    Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996;50:163-170.Google Scholar
  28. 28.
    Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B). 1972;34:187-220.Google Scholar
  29. 29.
    Larsen RH, Bruland ØS, Hoff Å, et al. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody; comparison with Astatine-21-labelled bovine serum albumon, free Astatine-211 and external-beam X rays. Rad Res. 1994;139:178-184.CrossRefGoogle Scholar
  30. 30.
    Larsen RH, Bruland ØS, Hoff P, et al. Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibodies. Br J Cancer. 1994;69:1000-1005.CrossRefPubMedGoogle Scholar
  31. 31.
    Olsen DR, Bruland ØS. Is osteosarcoma a radioresistant tumor? Towards the Eradication of Osteosarcoma Metastases – An Odyssey. The Norwegian Radium Hospital; 1998:73–76.Google Scholar
  32. 32.
    Sundaresan N, Rosen G, Ag H, et al. Combined treatment of osteosarcoma of the spine. Neurosurgery. 1988;23:714-719.CrossRefPubMedGoogle Scholar
  33. 33.
    Caceres E, Zaharia M, Valdivia S, et al. Local control of osteogenic sarcoma by radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1984;10:35-39.PubMedGoogle Scholar
  34. 34.
    Lombardi F, Gandola L, Fossati-Belani F, et al. Hypofractionated accelerated radiotherapy in osteogenic sarcoma. Int J Rad Oncol Biol Phys. 1992;24:761-765.CrossRefGoogle Scholar
  35. 35.
    Calvo FA, Ortiz de Urbina D, Sierrasesumaga L, et al. Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents. Med Pediatr Oncol. 1991;19:478-485.CrossRefPubMedGoogle Scholar
  36. 36.
    Hong A, Stevens G, Stalley P, et al. Extracorporeal irradiation for malignant bone tumors. Int J Radiat Oncol Biol Phys. 2001;50:441-447.CrossRefPubMedGoogle Scholar
  37. 37.
    Oya N, Kokubo M, Mizowaki T, et al. Definitive intraoperative very high-dose radiotherapy for localized osteosarcoma in the extremities. Int J Radiat Oncol Biol Phys. 2001;51:87-93.PubMedGoogle Scholar
  38. 38.
    Sabo D, Bernd L, Buchner M, et al. Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors. Orthopäde. 2003;32:1103-1112.CrossRefGoogle Scholar
  39. 39.
    Uhl V, Castro JR, Knopf K, et al. Preliminary results in heavy charged particle irradiation of bone sarcoma. Int J Radiat Oncol Biol Phys. 1992;24:755-759.CrossRefPubMedGoogle Scholar
  40. 40.
    Castro JR, Linstadt DE, Bhary JP, et al. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys. 1994;29:647-655.CrossRefPubMedGoogle Scholar
  41. 41.
    Hug EB, Munzenrieder JE. Charged particle therapy for base of skull tumors: Past accomplishments and future challenges. Int J Radiat Oncol Biol Phys. 1994;29:911-919.CrossRefPubMedGoogle Scholar
  42. 42.
    Kamada T, Tsujii H, Tsuji H, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20:4466-4471.CrossRefPubMedGoogle Scholar
  43. 43.
    Chambers RG, Mahoney WD. Osteogenic sarcoma of the mandible, current management. Am Surg. 1970;36:463-471.PubMedGoogle Scholar
  44. 44.
    Eilber FR, Morton DL, Eckhardt J, et al. Limb salvage for skeletal and soft tissue sarcomas: multidisciplinary preoperative therapy. Cancer. 1984;53:2579-2584.CrossRefPubMedGoogle Scholar
  45. 45.
    Dincbas FO, Koca S, Mandel NM, et al. The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int J Radiat Oncol Biol Phys. 2005;62:820-828.CrossRefPubMedGoogle Scholar
  46. 46.
    Carrie C, Breteau N, Negrier S, et al. The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report. Med Pediatr Onco. 1994;22:355-357.CrossRefGoogle Scholar
  47. 47.
    Burgers JM, van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs. Report of the EORTC-SIOP03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer. 1988;61:1024-1031.CrossRefPubMedGoogle Scholar
  48. 48.
    Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol. 2002;13:23-30.CrossRefPubMedGoogle Scholar
  49. 49.
    Appelbaum FR, Sandmaier B, Brown PA, et al. Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Imunoconjug Radiopharm. 1988;1:263-270.Google Scholar
  50. 50.
    Turner JH, Claringbold PG, Heytherington EL. A phase I study of samarium 153 ethylene diamine tetramethylene phosphonate therapy for dissiminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931.PubMedGoogle Scholar
  51. 51.
    Turner JH, Martindale AA, Sorby P. Samarium 153EDTMP therapy of dissiminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-795.CrossRefPubMedGoogle Scholar
  52. 52.
    Franzius C, Bielack S, Sciuk J, et al. High-activity samarium-EDTMP therapy followed by autologues peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001;40:215-220.PubMedGoogle Scholar
  53. 53.
    Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of Osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer. 2007;. doi:10.1002/pbc.21451.Google Scholar
  54. 54.
    Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin Proc. 2003;78:145-146.CrossRefPubMedGoogle Scholar
  55. 55.
    Jaffe N, Knapp J, Chuang VP, et al. Osteosarcomas: Intra-arterial treatment of the primary tumor with Cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51:402-407.CrossRefPubMedGoogle Scholar
  56. 56.
    Kinsella TJ, Glatstein E. Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer. 1987;59:908-915.CrossRefPubMedGoogle Scholar
  57. 57.
    Estrada-Aguilar J, Greenberg H, Walling A, et al. Primary treatment of pelvic osteosarcoma. Cancer. 1992;69:1137-1145.CrossRefPubMedGoogle Scholar
  58. 58.
    Martinez A, Goffinet DR, Donaldson SS, et al. Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. Int J Radiat Oncol Biol Phys. 1985;11:123-128.CrossRefPubMedGoogle Scholar
  59. 59.
    Anderson PM (2002) Samarium + gemcitabine concept. Presented at: Children’s Oncology Group meeting; October 26, St. Louis, Mo.Google Scholar
  60. 60.
    Anderson P, Aguilera D, Pearson M, et al. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control. 2008;15:38-46.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Rudolf Schwarz
    • 1
  • Oyvind Bruland
  • Anna Cassoni
  • Paula Schomberg
  • Stefan Bielack
  1. 1.Radiation Oncologist, Department of Radiation OncologyMedical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations